Iohexagita (Iohexol)

Iohexol contains iodine atoms that strongly absorb X‑rays. After intravenous or intra‑arterial injection, it circulates through the vascular system and temporarily raises the X‑ray attenuation of blood‑filled structures, creating a contrast difference between those structures and surrounding tissues, which produces detailed radiographic images.

The dose of Iohexagita is determined by the prescribing physician based on the specific imaging procedure, patient weight, renal function and the required level of contrast. Dosage calculations are individualized and should follow the relevant clinical guidelines and product labeling.

The safety of Iohexagita in pregnancy and lactation has not been definitively established. It is classified as pregnancy category unknown, and the decision to use it should be based on a careful risk‑benefit assessment by the treating physician, considering the importance of the diagnostic information.

To order Iohexagita, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including any cold‑chain requirements) and assist with import documentation.

Iohexagita (Iohexol) is a non‑ionic, low‑osmolality iodinated contrast medium, offering a favorable safety profile compared with older high‑osmolality agents. It provides comparable image quality while reducing the incidence of discomfort and adverse reactions, making it a preferred choice for many diagnostic imaging procedures.

Iohexagita should be stored below 25 °C in its original packaging, protected from light and moisture. The container must be kept sealed until use, and any opened vial should be used promptly according to the product’s stability guidelines to maintain sterility and efficacy.

Iohexagita is administered by a trained healthcare professional via intravenous or intra‑arterial injection. The injection rate and volume are tailored to the specific imaging study, and patients are monitored during and after administration for any immediate reactions.

The most serious risks include severe allergic reactions such as anaphylaxis, contrast‑induced nephropathy leading to acute renal failure, and rare cardiac events like arrhythmias or hypotension. Prompt recognition and management of these reactions are essential during and after administration.

Iohexagita should be avoided in patients with a known hypersensitivity to iodinated contrast agents, severe renal impairment without adequate hydration, uncontrolled hyperthyroidism, or those who are pregnant or breastfeeding unless the diagnostic benefit outweighs the potential risk.